Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 414 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 Woman with Breast Cancer May Have Saved Her Twin’s Life by... October 16, 2020 Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib May 22, 2026 Load more HOT NEWS Accepting Help During Cancer Is Hard, But It Can Benefit You... Does Too Much Fructose Help Colorectal Cancers Grow? Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia Reunión anual de la American Society of Clinical Oncology de 2022:...
